Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | MYLK | Q15746 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.46 |
| ▸ | TERT | O14746 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726702 | 0.92 | TERT (0.52) | HDAC4HPGDSEGFRTERTNPC1 | |
| SCHEMBL27193028 | 0.88 | HDAC4 (0.53) | HDAC4HPGDSEGFRMYLKKDM4E | |
| SCHEMBL13778305 | 0.84 | HPGDS (0.55) | HDAC4HPGDSSIRT2SIRT1TERT | |
| SCHEMBL12011576 | 0.84 | HDAC4 (0.60) | HDAC4KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL17555519 | 0.82 | HDAC4 (0.48) | HDAC4KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL24569018 | 0.82 | HDAC4 (0.47) | HDAC4HPGDSEGFRMYLKKDM4E | |
| SCHEMBL24568425 | 0.82 | HDAC4 (0.57) | HDAC4LTA4HKDM4ENPC1ALDH1A1 | |
| SCHEMBL24568421 | 0.81 | HDAC4 (0.60) | HDAC4EGFRKDM4ENPC1ALDH1A1 | |
| SCHEMBL12011629 | 0.81 | HDAC4 (0.55) | HDAC4KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL16010977 | 0.80 | HDAC4 (0.65) | HDAC4EGFRLTA4HKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-04-11 | — | — | US | disclosed |
| EP-4267584-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136221-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136221-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-30 | — | — | WO | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, TGFBR2 | HDAC4 2697/4885HPGDS 1652/4885EGFR 84/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | HDAC4 1958/4885HPGDS 1987/4885EGFR 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.